NCT02670070View on ClinicalTrials.gov

BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone

PHASE1UnknownINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2016

Conditions

Healthy

Interventions

DRUG

gemigliptin 50mg, rosuvastatin 20mg

gemigliptin/rosuvastatin 50/20mg

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY

NCT02670070 - BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone | Biotech Hunter | Biotech Hunter